| ¿µ¹® | coagulation necrosis | ÇÑ±Û | ÀÀ°í±«»ç |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷ÀÇ Á×À½À» ³ªÅ¸³»´Â ÇüÅÂÇÐÀû º¯È·Î¼ ±«»çºÎÀ§°¡ ÀÀ°íÇÑ »óÅ·ΠÀÖ´Â °Í. ±«»ç¼¼Æ÷´Â È£»ê¼º µ¢¾î¸®·Î º¸À̸ç Àû¾îµµ ¼öÀϰ£ ¼¼Æ÷ÀÇ ±âº» À±°ûÀÌ º¸Á¸µÇ±â ¶§¹®¿¡ Á¶Á÷±¸Á¶¸¦ ½Äº°ÇÒ ¼ö ÀÖ´Ù. ´ëÇ¥ÀûÀ¸·Î ÇãÇ÷±«»ç¸¦ µé ¼ö ÀÖ´Ù. °æ»ö°ú ÇãÇ÷¿¡ ÀÇÇÑ Àú»ê¼ÒÁõ½Ã ½ÉÀå±ÙÀ̳ª ÄáÆÏ¿¡¼ °üÂûµÇ°Å³ª Àü±â ¹× ¼öÀºÁßµ¶½Ã ÄáÆÏÀÇ ¿ä¼¼°ü¿¡¼ °üÂûµÇ´Â °ÍÀ¸·Î ´Ü¹éÀÇ º¯¼º ÈÄ ³²¾ÆÀֱ⠶§¹®ÀÌ´Ù. ¼¼Æ÷ÀÇ À±°ûÀÌ ³²¾Æ ÀÖ¾î ¿ø·¡ Á¶Á÷ÀÇ ±¸Á¶¸¦ ÇüÅÂÇÐÀûÀ¸·Î ÀνÄÇÒ ¼ö ÀÖ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. |
||
| ¿µ¹® | coagulation time | ÇÑ±Û | ÀÀ°í½Ã°£ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò¶õ ¹°ÁúÀº ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. Ç÷¾×ÀÀ°í´Â ´ÙÀ½°ú °°Àº 3´Ü°è·Î ÀÌ·ç¾îÁø´Ù. ù¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼ prothrombin activator¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ prothrombin activator¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ Ç÷¾×¼Ó¿¡ ÀÖ´Â ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ÀÀ°íÀÛ¿ëÀº Å©°Ô 2°¡Áö·Î ³ª´µ´Âµ¥, ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ°¡ ±×°ÍÀÌ´Ù. ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ´Â °¢±â º°°³·Î ÀÛ¿ëÇÏÁö¸¸, °á±¹Àº ¸¶Áö¸· °úÁ¤¿¡¼ Çϳª·Î ¸¸³ª¼ ¼¶À¯¼Ò¿øÀ» ¼¶À¯¼Ò(ÀÀ°íÀÛ¿ëÀÇ ¸¶Áö¸· ´Ü°è¿¡ »ý¼ºµÇ¸ç ´Ü´ÜÇϰí Ç®¸®Áö ¾Ê´Â ¸ÅµìÀ» Çü¼ºÇÏ¿© ÁöÇ÷ÀÛ¿ëÀ» ¿Ï¼ºÇÑ´Ù)À¸·Î ¸¸µé¾î ÀÀ°íÀÛ¿ëÀ» ³ªÅ¸³½´Ù. |
||
| ¿µ¹® | fasting blood sugar | ÇÑ±Û | °øº¹Ç÷´ç, ºó¼ÓÇ÷´ç |
|---|---|---|---|
| ¼³¸í | Ç÷¾×¼Ó¿¡ Æ÷ÇԵǾî ÀÖ´Â Æ÷µµ´ç. ³ú¿Í ÀûÇ÷±¸ÀÇ ¿¡³ÊÁö¿øÀÌ µÇ°í, ±× ¾çÀº ¿îµ¿, ½Ä»ç µûÀ§¿¡ ÀÇÇÏ¿© ´Þ¶óÁø´Ù. °Ç°ÀÎÀÇ ¾ÆÄ§ °øº¹½Ã Ç÷Áß Æ÷µµ´ç ³óµµ´Â 60~100mg/dLÀÌÁö¸¸ ±âŸÀÇ ´çÁú Áï °ú´ç, °¥¶ôÅ佺, 5ź´çÀº ¹Ì·®À̸ç ÀϹÝÀûÀ¸·Î Ç÷´çÀÏ Çϸé Ç÷Á߯÷µµ´çÀ» ÀǹÌÇÑ´Ù. Ç÷´çÀº »ýüÀÇ ¿¡³ÊÁö¿øÀ¸·Î¼ °¡Àå Áß¿äÇÑ ¹°ÁúÀÌ´Ù. ±× ³óµµ´Â âÀÚ°üÀ¸·ÎºÎÅÍÀÇ Èí¼ö, °£¿¡ ÀÖ¾î¼ÀÇ ´ç½Å»ý°ú ±Û¸®ÄÚ°ÕÀÇ ÇÕ¼º-ºÐÇØ, ¸»ÃÊÁ¶Á÷ÀÇ ´çÀÌ¿ë, ÄáÆÏÀ¸·ÎºÎÅÍÀÇ ¹è¼³ µî ¿©·¯ ÀÎÀÚ¿¡ÀÇÇØ Á¿ìµÇ¸ç ±× Á¶Àý¿¡´Â ÀÚÀ²½Å°æ°ú °¢Á¾ È£¸£¸óÀÌ ¹ÐÁ¢ÇÏ°Ô °ü°èÇÑ´Ù. ƯÈ÷ Ç÷´çÀúÇÏÀÛ¿ë¿¡´Â Àν¶¸°ÀÌ, ±×¸®°í Ç÷´ç»ó½ÂÀÛ¿ë¿¡´Â ¿¡Çdz×ÇÁ¸°, ±Û·çÄ«°ï, ¼ºÀåÈ£¸£¸ó, ºÎ½Å°ÑÁúÈ£¸£¸ó, ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó, °©»ó»ù È£¸£¸óÀÌ °ü°è°¡ ÀÖÀ¸¸ç ±×°ÍµéÀÇ ´ëÇ× ¹× ÇùÁ¶ ÀÛ¿ë¿¡ ÀÇÇØ Ç÷´çÄ¡°¡ Á¶ÀýµÈ´Ù. |
||
| ¿µ¹® | white blood cell(WBC), leukocyte | ÇÑ±Û | ¹éÇ÷±¸ |
|---|---|---|---|
| ¼³¸í | Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, ȤÀº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀÎ Çö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù. |
||
| ¿µ¹® | whole blood | ÇÑ±Û | ÀüÇ÷, ¿ÂÇ÷¾× |
|---|---|---|---|
| ¼³¸í | Ç÷¾×ÀÇ ¸ðµç ¼ººÐÀÌ Çϳªµµ Á¦°ÅµÇÁö ¾ÊÀº ¿ÂÀüÇÑ Ç÷¾×. ÀüÇ÷Àº ¾ö°ÝÇÑ ¹«±ÕÁ¶°ÇÇÏ¿¡¼, ¼±º°ÇÑ °øÇ÷ÀڷκÎÅÍ Ã¤ÃëÇÑ °ÍÀ̸ç, ±¸¿¬»ê ÀÌ¿ÂÀ̳ª ÇìÆÄ¸° °°Àº Ç×ÀÀ°øÁ¦·Î ÀÀ°í¸¦ ¹æÁöÇÏ¿© Ç÷¾×º¸Ãæ ¸ñÀûÀ¸·Î »ç¿ëÇÑ´Ù. |
||
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
|---|---|
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| F2R | [blood coagulation] factor II receptor |
| CCF | cancer coagulation factor; cardiolipin complement fixation; carotid-cavernous fistula; centrifuged c... |
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
| coagulation | 1. <haematology> The process of clot formation. 2. <chemistry> The solidification of a sol into a gelatinous mass, an alteration of a disperse phase or of a dissolved solid which causes the separation of the system into a liquid phase and an insoluble mass called the clot or curd. Coagulation is usually irreversible. 3. <surgery> The disruption of tissue by physical means to form an amorphous residuum, as in electrocoagulation and photocoagulation. Origin: L. Coagulatio (18 Nov 1997) |
|---|---|
| coagulation necrosis | A type of necrosis in which the affected cells or tissue are converted into a dry, dull, fairly homogeneous eosinophilic mass without nuclear staining, as a result of the coagulation of protein as occurs in an infarct; microscopically, the necrotic process involves chiefly the cells, and remnants of histologic elements (e.g., elastin, collagen, muscle fibres) may be recognizable, as well as "ghosts" of cells and portions of cell membranes; may be caused by heat, ischemia, and other agents that destroy tissue, including enzymes that would continue to alter the devitalised cellular substance. (05 Mar 2000) |
| coagulation profile | A test which measures the speed of blood coagulation at different steps of the coagulation pathway. (27 Sep 1997) |
| coagulation time | The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases. Synonym: clotting time. (05 Mar 2000) |
| coagulation vitamin | An obsolete term for vitamin K. (05 Mar 2000) |
| heat coagulation test | A test for measurement of protein in urine; albumin and globulin are coagulated by heat at an acid pH, and the amount of turbidity present provides a qualitative estimation of the degree of proteinuria. (05 Mar 2000) |
| disseminated intravascular coagulation | <haematology> Complication of septic shock in which endotoxin (from gram-negative bacteria) induces systemic clotting of the blood, probably indirectly through the effect of endotoxin on neutrophils. It may also develop in other situations where neutrophils become systemically hyperactivated. Acronym: DIC (11 Jan 1998) |
| laser coagulation | The coagulation of tissues using lasers. These lasers produce light in the visible green wavelength that is selectively absorbed by haemoglobin, and thus it is possible to seal bleeding blood vessels. (12 Dec 1998) |
| light coagulation | The coagulation of tissue by an intense beam of light, including laser (laser coagulation). In the eye it is used in the treatment of retinal detachments, retinal holes, aneurysms, haemorrhages, and malignant and benign neoplasms. (12 Dec 1998) |
| lipoprotein-associated coagulation inhibitor | Formerly known as anticonvertin; a protein that inhibits the extrinsic pathway of coagulation by binding to the tissue factor III-factor VII-Calcium-factor Xa complex. (05 Mar 2000) |
| lupus coagulation inhibitor | An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications. (12 Dec 1998) |
| blood clotting factor | <haematology> Any of a number of different protein factors which, when acting together, can form a blood clot shortly after platelets have broken at the site of the wound. The factors have Roman numeral names, like VII, VIII, IX, X, XI, and XIII. Defects in the genes which code for any of these factors result in genetic diseases like haemophilia, which results from a defect in the gene for factor VIII or IX. (09 Oct 1997) |
| recombinant | <molecular biology> A cell or an individual with a new combination of genes not found together in either parent, usually applied to linked genes. (18 Nov 1997) |
| recombinant clone | <molecular biology> Clones containing recombinant DNA molecules. See: recombinant DNA technologies. (14 Oct 1997) |
| recombinant clones | Clones containing recombinant DNA molecules. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|